These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34856043)

  • 1. Direct and Catalytic C-Glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside.
    Obradors C; Mitschke B; Aukland MH; Leutzsch M; Grossmann O; Brunen S; Schwengers SA; List B
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202114619. PubMed ID: 34856043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir.
    Wang M; Zhang L; Huo X; Zhang Z; Yuan Q; Li P; Chen J; Zou Y; Wu Z; Zhang W
    Angew Chem Int Ed Engl; 2020 Nov; 59(47):20814-20819. PubMed ID: 32870563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.
    Knapp RR; Tona V; Okada T; Sarpong R; Garg NK
    Org Lett; 2020 Nov; 22(21):8430-8435. PubMed ID: 33085486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of Nucleoside-like Molecules from a Pyrolysis Product of Cellulose and Their Computational Prediction as Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors.
    Defant A; Dosi F; Innocenti N; Mancini I
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad-Spectrum
    Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Murphy J; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou CF
    Microbiol Spectr; 2021 Dec; 9(3):e0153721. PubMed ID: 34817209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
    Sreekanth Reddy O; Lai WF
    Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.
    Xie Y; Hu T; Zhang Y; Wei D; Zheng W; Zhu F; Tian G; Aisa HA; Shen J
    J Org Chem; 2021 Apr; 86(7):5065-5072. PubMed ID: 33733767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Chemoenzymatic Synthesis of the (
    Bigley AN; Narindoshvili T; Raushel FM
    Biochemistry; 2020 Aug; 59(33):3038-3043. PubMed ID: 32786401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
    Deb S; Reeves AA
    J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the molecular structure of Remdesivir for the treatment of Covid-19.
    Sheikholeslami SM; Jahanbani A; Shao Z
    Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir: Quo vadis?
    De Clercq E
    Biochem Pharmacol; 2021 Nov; 193():114800. PubMed ID: 34678228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2.
    Xie Y; Yin W; Zhang Y; Shang W; Wang Z; Luan X; Tian G; Aisa HA; Xu Y; Xiao G; Li J; Jiang H; Zhang S; Zhang L; Xu HE; Shen J
    Cell Res; 2021 Nov; 31(11):1212-1214. PubMed ID: 34584244
    [No Abstract]   [Full Text] [Related]  

  • 14. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-Target
    Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Remdesivir, the antiviral hope against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2020 Jun; 33(3):176-179. PubMed ID: 32239125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir: From Ebola to COVID-19.
    Santoro MG; Carafoli E
    Biochem Biophys Res Commun; 2021 Jan; 538():145-150. PubMed ID: 33388129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.